How vitreomacular interface modifies the efficacy of anti-vegf therapy for myopic choroidal neovascularization

Conclusion: The data show that ranibizumab is effective in controlling mCNV activity when associated with vitreoretinal interface alterations. However, a visual recovery was observed only in patients with uncomplicated mCNV.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research